Rakovina Therapeutics Inc. (RKV.V)
| Previous Close | 0.0850 |
| Open | 0.0900 |
| Bid | 0.0850 x N/A |
| Ask | 0.0900 x N/A |
| Day's Range | 0.0850 - 0.0900 |
| 52 Week Range | 0.0050 - 0.1350 |
| Volume | |
| Avg. Volume | 30,560 |
| Market Cap | 7.675M |
| Beta (5Y Monthly) | 0.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Nov 25, 2024 - Nov 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration
Companies will jointly research DNA-damage response kinase targets to identify potential drug candidates for the treatment of cancerVANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies and Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, announced today a research colla
- GlobeNewswire
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the second quarter ending June 30, 2024, and provides an update to corporate activities. "We are thrilled by the rapid progress and strategic advancemen
- GlobeNewswire
Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement
All dollar amounts reflected in Canadian dollars unless otherwise stated.VANCOUVER, British Columbia, July 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, announces that, further to the press releases dated May 23, 2024, June 20, 2024, July 19, 2024, and July 22, 2024, the Company has closed its previously announced over-subscribed non-bro
